Trade Lisata Therapeutics, Inc - LSTA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.18 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 2.58 |
Open* | 2.51 |
1-Year Change* | -19.81% |
Day's Range* | 2.38 - 2.62 |
52 wk Range | 0.40-1.26 |
Average Volume (10 days) | 131.69K |
Average Volume (3 months) | 2.95M |
Market Cap | 30.92M |
P/E Ratio | -100.00K |
Shares Outstanding | 60.58M |
Revenue | N/A |
EPS | -0.41 |
Dividend (Yield %) | N/A |
Beta | 0.91 |
Next Earnings Date | Nov 2, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 7, 2023 | 2.58 | 0.49 | 23.44% | 2.09 | 2.69 | 2.09 |
Dec 6, 2023 | 2.44 | 0.29 | 13.49% | 2.15 | 2.57 | 2.09 |
Dec 5, 2023 | 2.19 | -0.07 | -3.10% | 2.26 | 2.29 | 2.11 |
Dec 4, 2023 | 2.25 | 0.14 | 6.64% | 2.11 | 2.25 | 2.07 |
Dec 1, 2023 | 2.14 | 0.06 | 2.88% | 2.08 | 2.14 | 2.08 |
Nov 30, 2023 | 2.17 | -0.17 | -7.26% | 2.34 | 2.38 | 2.06 |
Nov 29, 2023 | 2.43 | 0.04 | 1.67% | 2.39 | 2.43 | 2.22 |
Nov 28, 2023 | 2.39 | 0.06 | 2.58% | 2.33 | 2.41 | 2.24 |
Nov 27, 2023 | 2.41 | -0.03 | -1.23% | 2.44 | 2.48 | 2.39 |
Nov 24, 2023 | 2.29 | 0.05 | 2.23% | 2.24 | 2.43 | 2.24 |
Nov 22, 2023 | 2.24 | 0.15 | 7.18% | 2.09 | 2.24 | 2.04 |
Nov 21, 2023 | 2.16 | 0.07 | 3.35% | 2.09 | 2.21 | 2.09 |
Nov 20, 2023 | 2.19 | 0.00 | 0.00% | 2.19 | 2.20 | 2.09 |
Nov 17, 2023 | 2.23 | 0.03 | 1.36% | 2.20 | 2.26 | 2.19 |
Nov 16, 2023 | 2.24 | 0.05 | 2.28% | 2.19 | 2.25 | 2.19 |
Nov 15, 2023 | 2.23 | 0.01 | 0.45% | 2.22 | 2.24 | 2.14 |
Nov 14, 2023 | 2.22 | 0.13 | 6.22% | 2.09 | 2.24 | 2.09 |
Nov 13, 2023 | 2.12 | 0.03 | 1.44% | 2.09 | 2.13 | 2.09 |
Nov 10, 2023 | 2.13 | 0.00 | 0.00% | 2.13 | 2.20 | 2.06 |
Nov 9, 2023 | 2.09 | -0.08 | -3.69% | 2.17 | 2.22 | 2.02 |
Lisata Therapeutics, Inc Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 28, 2024 | ||
Time (UTC) 20:00 | Country US
| Event Q4 2023 Lisata Therapeutics Inc Earnings Release Q4 2023 Lisata Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 29.05 | 19.145 | 20.092 | 16.987 | 27.593 |
Selling/General/Admin. Expenses, Total | 11.37 | 9.892 | 9.295 | 9.393 | 11.7501 |
Research & Development | 17.68 | 9.253 | 10.797 | 7.594 | 15.843 |
Operating Income | -29.05 | -19.145 | -20.092 | -16.987 | -27.593 |
Interest Income (Expense), Net Non-Operating | 0.151 | 0 | -0.005 | -0.37777 | |
Other, Net | -0.075 | 0.132 | 0.74 | 0.824 | 0.2731 |
Net Income Before Taxes | -28.974 | -19.013 | -19.352 | -16.168 | -27.6977 |
Net Income After Taxes | -27.466 | -8.141 | -19.352 | -16.168 | -16.1712 |
Minority Interest | 0 | -0.009 | -0.009 | 0.001 | 0.18246 |
Net Income Before Extra. Items | -27.466 | -8.15 | -19.361 | -16.167 | -15.9887 |
Total Extraordinary Items | 0 | 38.9674 | |||
Net Income | -27.466 | -8.15 | -19.361 | -16.167 | 22.9787 |
Income Available to Common Excl. Extra. Items | -27.466 | -8.15 | -19.361 | -16.167 | -15.9887 |
Income Available to Common Incl. Extra. Items | -27.466 | -8.15 | -19.361 | -16.167 | 22.9787 |
Diluted Net Income | -27.466 | -8.15 | -19.361 | -16.167 | 22.9787 |
Diluted Weighted Average Shares | 55.313 | 15.44 | 10.325 | 9.689 | 8.96895 |
Diluted EPS Excluding Extraordinary Items | -0.49656 | -0.52785 | -1.87516 | -1.66859 | -1.78267 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -0.49656 | -0.52785 | -1.87516 | -1.66859 | -1.78267 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 6.62 | 6.849 | 6.968 | 7.147 | 8.086 |
Selling/General/Admin. Expenses, Total | 3.342 | 2.699 | 2.843 | 2.818 | 3.01 |
Research & Development | 3.278 | 4.15 | 4.125 | 4.329 | 5.076 |
Operating Income | -6.62 | -6.849 | -6.968 | -7.147 | -8.086 |
Interest Income (Expense), Net Non-Operating | 0.063 | 0.04 | 0.041 | 0.047 | 0.023 |
Net Income Before Taxes | -6.705 | -6.794 | -6.927 | -7.19 | -8.063 |
Net Income After Taxes | -4.226 | -6.794 | -6.927 | -5.682 | -8.063 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Net Income Before Extra. Items | -4.226 | -6.794 | -6.927 | -5.682 | -8.063 |
Net Income | -4.226 | -6.794 | -6.927 | -5.682 | -8.063 |
Income Available to Common Excl. Extra. Items | -4.226 | -6.794 | -6.927 | -5.682 | -8.063 |
Income Available to Common Incl. Extra. Items | -4.226 | -6.794 | -6.927 | -5.682 | -8.063 |
Diluted Net Income | -4.226 | -6.794 | -6.927 | -5.682 | -8.063 |
Diluted Weighted Average Shares | 60.56 | 59.819 | 59.614 | 59.51 | 42.117 |
Diluted EPS Excluding Extraordinary Items | -0.06978 | -0.11358 | -0.1162 | -0.09548 | -0.19144 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -0.06978 | -0.11358 | -0.1162 | -0.09548 | -0.19144 |
Other, Net | -0.148 | 0.015 | 0 | -0.09 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 96.182 | 35.331 | 25.972 | 44.106 | 61.397 |
Cash and Short Term Investments | 94.97 | 34.573 | 25.157 | 43.053 | 55.08 |
Cash & Equivalents | 24.647 | 16.512 | 14.032 | 10.299 | 29.163 |
Short Term Investments | 70.323 | 18.061 | 11.125 | 32.754 | 25.917 |
Total Receivables, Net | |||||
Accounts Receivable - Trade, Net | |||||
Prepaid Expenses | 1.212 | 0.758 | 0.815 | 1.053 | 1.312 |
Other Current Assets, Total | 0 | 5.005 | |||
Total Assets | 97.008 | 36.002 | 27.153 | 44.58 | 63.376 |
Property/Plant/Equipment, Total - Net | 0.786 | 0.631 | 1.006 | 0.165 | 0.257 |
Other Long Term Assets, Total | 0.04 | 0.04 | 0.175 | 0.309 | 1.722 |
Total Current Liabilities | 4.523 | 3.506 | 5.976 | 5.619 | 9.314 |
Accounts Payable | 1.934 | 1.02 | 1.49 | 0.762 | 1.343 |
Accrued Expenses | 2.589 | 2.486 | 4.486 | 4.857 | 7.812 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.159 | |||
Other Current Liabilities, Total | |||||
Total Liabilities | 4.754 | 3.506 | 6.337 | 6.854 | 12.869 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Minority Interest | -0.254 | -0.254 | -0.263 | -0.272 | -0.318 |
Other Liabilities, Total | 0.485 | 0.254 | 0.624 | 1.507 | 3.873 |
Total Equity | 92.254 | 32.496 | 20.816 | 37.726 | 50.507 |
Common Stock | 0.06 | 0.019 | 0.011 | 0.01 | 0.009 |
Additional Paid-In Capital | 545.988 | 458.748 | 438.911 | 436.433 | 433.044 |
Retained Earnings (Accumulated Deficit) | -453.016 | -425.55 | -417.4 | -397.977 | -381.81 |
Treasury Stock - Common | -0.708 | -0.708 | -0.708 | -0.708 | -0.708 |
Other Equity, Total | -0.07 | -0.013 | 0.002 | -0.032 | -0.028 |
Total Liabilities & Shareholders’ Equity | 97.008 | 36.002 | 27.153 | 44.58 | 63.376 |
Total Common Shares Outstanding | 59.7897 | 19.3783 | 10.5176 | 9.85466 | 9.47283 |
Total Preferred Shares Outstanding | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Property/Plant/Equipment, Total - Gross | 1.154 | 0.944 | 1.255 | ||
Accumulated Depreciation, Total | -0.368 | -0.313 | -0.249 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 90.7 | 96.182 | 102.107 | 108.08 | 114.033 |
Cash and Short Term Investments | 88.519 | 94.97 | 100.149 | 106.09 | 111.511 |
Cash & Equivalents | 12.747 | 24.647 | 12.772 | 12.935 | 28.744 |
Short Term Investments | 75.772 | 70.323 | 87.377 | 93.155 | 82.767 |
Prepaid Expenses | 2.181 | 1.212 | 1.958 | 1.99 | 2.522 |
Total Assets | 91.463 | 97.008 | 102.538 | 108.614 | 114.607 |
Property/Plant/Equipment, Total - Net | 0.722 | 0.786 | 0.392 | 0.492 | 0.533 |
Other Long Term Assets, Total | 0.041 | 0.04 | 0.039 | 0.042 | 0.041 |
Total Current Liabilities | 2.801 | 4.523 | 4.072 | 3.856 | 4.438 |
Accounts Payable | 0.697 | 1.934 | 0.768 | 1.242 | 2.315 |
Accrued Expenses | 2.104 | 2.589 | 3.304 | 2.614 | 2.123 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.968 | 4.754 | 3.871 | 3.681 | 4.339 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -0.254 | -0.254 | -0.254 | -0.254 | -0.254 |
Other Liabilities, Total | 0.421 | 0.485 | 0.053 | 0.079 | 0.155 |
Total Equity | 88.495 | 92.254 | 98.667 | 104.933 | 110.268 |
Common Stock | 0.061 | 0.06 | 0.06 | 0.06 | 0.06 |
Additional Paid-In Capital | 546.58 | 545.988 | 545.601 | 544.893 | 544.601 |
Retained Earnings (Accumulated Deficit) | -457.242 | -453.016 | -446.222 | -439.295 | -433.613 |
Treasury Stock - Common | -0.708 | -0.708 | -0.708 | -0.708 | -0.708 |
Other Equity, Total | -0.196 | -0.07 | -0.064 | -0.017 | -0.072 |
Total Liabilities & Shareholders’ Equity | 91.463 | 97.008 | 102.538 | 108.614 | 114.607 |
Total Common Shares Outstanding | 60.5331 | 59.7897 | 59.7799 | 59.5175 | 59.499 |
Total Preferred Shares Outstanding | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -27.466 | -8.141 | -19.352 | -16.168 | 22.2281 |
Cash From Operating Activities | -22.245 | -8.823 | -18.882 | -19.986 | -20.8759 |
Cash From Operating Activities | 0.055 | 0.063 | 0.065 | 0.225 | 0.372 |
Deferred Taxes | 0 | -12.1016 | |||
Non-Cash Items | 4.519 | 1.572 | 1.527 | 1.306 | -36.5223 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0 | 0 | 0 | 0.005 | 0.7119 |
Changes in Working Capital | 0.647 | -2.317 | -1.122 | -5.349 | 5.14797 |
Cash From Investing Activities | -54.896 | -7.277 | 21.432 | -4.707 | 41.2706 |
Capital Expenditures | -0.06 | -0.02 | 0 | -0.134 | -0.13528 |
Other Investing Cash Flow Items, Total | -54.836 | -7.257 | 21.432 | -4.573 | 41.4059 |
Cash From Financing Activities | 85.276 | 18.58 | 1.183 | 0.824 | -0.93177 |
Financing Cash Flow Items | -0.248 | -0.148 | -0.13 | -0.403 | -0.4319 |
Issuance (Retirement) of Stock, Net | 85.524 | 18.728 | 1.313 | 1.386 | 5.71526 |
Issuance (Retirement) of Debt, Net | 0 | -0.159 | -6.21513 | ||
Net Change in Cash | 8.135 | 2.48 | 3.733 | -23.869 | 19.463 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.226 | -27.466 | -20.672 | -13.745 | -8.063 |
Cash From Operating Activities | -5.642 | -22.245 | -17.641 | -12.602 | -7.975 |
Cash From Operating Activities | 0.007 | 0.055 | 0.047 | 0.033 | 0.016 |
Non-Cash Items | 1.275 | 4.519 | 3.564 | 2 | 0.92 |
Changes in Working Capital | -2.698 | 0.647 | -0.58 | -0.89 | -0.848 |
Cash From Investing Activities | -6.09 | -54.896 | -71.354 | -76.294 | -65.09 |
Capital Expenditures | -0.06 | -0.06 | -0.06 | 0 | |
Other Investing Cash Flow Items, Total | -6.09 | -54.836 | -71.294 | -76.234 | -65.09 |
Cash From Financing Activities | -0.168 | 85.276 | 85.255 | 85.319 | 85.297 |
Financing Cash Flow Items | -0.168 | -0.248 | -0.248 | -0.184 | -0.184 |
Issuance (Retirement) of Stock, Net | 0 | 85.524 | 85.503 | 85.503 | 85.481 |
Net Change in Cash | -11.9 | 8.135 | -3.74 | -3.577 | 12.232 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lisata Therapeutics, Inc Company profile
About Caladrius Biosciences Inc
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).
Financial summary
BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).
Equity composition
Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.
Industry: | Biotechnology & Medical Research (NEC) |
110 Allen Road
Second Floor
07920
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com